Rapamycin does not improve insulin sensitivity despite elevated mammalian target of rapamycin complex 1 activity in

Andrew M Miller1, Jonathan R Brestoff, Charles B Phelps

  • 1Dept. of Exercise Science, Skidmore College, 815 North Broadway, Saratoga Springs, NY 12866, USA.

Insights

Elevated mammalian target of rapamycin complex 1 (mTORC1) signaling in obese mice did not cause insulin resistance. Rapamycin treatment did not improve glucose or insulin tolerance, indicating other factors mediate insulin resistance in obesity.

Area of Science:

  • Biochemistry
  • Physiology
  • Metabolic Diseases

Background:

  • Mammalian target of rapamycin complex 1 (mTORC1) is implicated in insulin resistance in cell studies.
  • The role of mTORC1 in skeletal muscle insulin resistance is not well-established.

Purpose of the Study:

  • To investigate mTORC1 activity in skeletal muscles of obese (ob/ob) mice compared to wild-type (WT) mice.
  • To determine the contribution of mTORC1 to insulin resistance in skeletal muscle.

Main Methods:

  • Assessed in vivo insulin action in mouse skeletal muscle.
  • Measured phosphorylation of key signaling proteins (S6K, mTOR, PRAS40, PKB) in basal and insulin-stimulated states.
  • Administered rapamycin to assess its effects on glucose and insulin tolerance.

Main Results:

  • Obese mice exhibited increased basal mTORC1 signaling and basal PKB phosphorylation.
  • Insulin-stimulated PKB phosphorylation was reduced in obese mice.
  • Rapamycin treatment did not improve glucose or insulin tolerance in obese mice.

Conclusions:

  • Increased mTORC1 activity in obese mice is not the primary driver of skeletal muscle insulin resistance.
  • Factors other than mTORC1 contribute to insulin resistance in this model.
  • Targeting mTORC1 may not be an effective strategy for treating obesity-induced insulin resistance.